126 related articles for article (PubMed ID: 9126154)
1. L-Dopa and dopamine-producing gene cassettes for gene therapy approaches to Parkinson's disease.
Moffat M; Harmon S; Haycock J; O'Malley KL
Exp Neurol; 1997 Mar; 144(1):69-73. PubMed ID: 9126154
[TBL] [Abstract][Full Text] [Related]
2. [Gene therapy of tyrosine hydroxylase, aromatic L-amino acid decarboxylase, and GTP cyclohydrolase genes in rat model of Parkinson's disease].
Lu LL; Su Y; Duan CL; Zhao CL; Su YJ; Wu J; Zhao HY; Xu QY; Yang H
Zhonghua Yi Xue Za Zhi; 2004 Sep; 84(18):1528-32. PubMed ID: 15500713
[TBL] [Abstract][Full Text] [Related]
3. [Expression and assessment of double genes of tyrosine hydroxylase gene and aromatic L-amino acid decarboxylase gene in vitro].
Su Y; Duan CL; Zhao CL; Zhao HY; Xu QY; Yang H
Sheng Li Xue Bao; 2003 Oct; 55(5):583-8. PubMed ID: 14566408
[TBL] [Abstract][Full Text] [Related]
4. In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector.
During MJ; Samulski RJ; Elsworth JD; Kaplitt MG; Leone P; Xiao X; Li J; Freese A; Taylor JR; Roth RH; Sladek JR; O'Malley KL; Redmond DE
Gene Ther; 1998 Jun; 5(6):820-7. PubMed ID: 9747462
[TBL] [Abstract][Full Text] [Related]
5. Gene therapy for Parkinson's disease: determining the genes necessary for optimal dopamine replacement in rat models.
Kang UJ; Lee WY; Chang JW
Hum Cell; 2001 Mar; 14(1):39-48. PubMed ID: 11436352
[TBL] [Abstract][Full Text] [Related]
6. The assays of activities and function of TH, AADC, and GCH1 and their potential use in ex vivo gene therapy of PD.
Duan CL; Su Y; Zhao CL; Lu LL; Xu QY; Yang H
Brain Res Brain Res Protoc; 2005 Dec; 16(1-3):37-43. PubMed ID: 16338639
[TBL] [Abstract][Full Text] [Related]
7. Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase gene therapy prevents development of motor complications in parkinsonian rats after chronic intermittent L-3,4-dihydroxyphenylalanine administration.
Lee WY; Lee EA; Jeon MY; Kang HY; Park YG
Exp Neurol; 2006 Jan; 197(1):215-24. PubMed ID: 16269145
[TBL] [Abstract][Full Text] [Related]
8. Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats.
Sánchez-Pernaute R; Harvey-White J; Cunningham J; Bankiewicz KS
Mol Ther; 2001 Oct; 4(4):324-30. PubMed ID: 11592835
[TBL] [Abstract][Full Text] [Related]
9. Role of aromatic L-amino acid decarboxylase for dopamine replacement by genetically modified fibroblasts in a rat model of Parkinson's disease.
Wachtel SR; Bencsics C; Kang UJ
J Neurochem; 1997 Nov; 69(5):2055-63. PubMed ID: 9349551
[TBL] [Abstract][Full Text] [Related]
10. Gene therapy for Parkinson's disease.
Lawlor PA; During MJ
Expert Rev Mol Med; 2004 Mar; 6(5):1-18. PubMed ID: 15000692
[TBL] [Abstract][Full Text] [Related]
11. Adeno-associated virus-mediated gene transfer of human aromatic L-amino acid decarboxylase protects mixed striatal primary cultures from L-DOPA toxicity.
Doroudchi MM; Liauw J; Heaton K; Zhen Z; Forsayeth JR
J Neurochem; 2005 May; 93(3):634-40. PubMed ID: 15836622
[TBL] [Abstract][Full Text] [Related]
12. [Present status and future prospects for gene therapy in Parkinson's disease].
Muramatsu S
Nihon Naika Gakkai Zasshi; 2003 Aug; 92(8):1461-6. PubMed ID: 13677895
[No Abstract] [Full Text] [Related]
13. Rat marrow stromal cells rapidly transduced with a self-inactivating retrovirus synthesize L-DOPA in vitro.
Schwarz EJ; Reger RL; Alexander GM; Class R; Azizi SA; Prockop DJ
Gene Ther; 2001 Aug; 8(16):1214-23. PubMed ID: 11509954
[TBL] [Abstract][Full Text] [Related]
14. The ability of grafted human sympathetic neurons to synthesize and store dopamine: a potential mechanism for the clinical effect of sympathetic neuron autografts in patients with Parkinson's disease.
Nakao N; Shintani-Mizushima A; Kakishita K; Itakura T
Exp Neurol; 2004 Jul; 188(1):65-73. PubMed ID: 15191803
[TBL] [Abstract][Full Text] [Related]
15. [AAV vector-mediated gene transfer and its application to the nervous system].
Ozawa K
Rinsho Shinkeigaku; 2003 Nov; 43(11):835-8. PubMed ID: 15152479
[TBL] [Abstract][Full Text] [Related]
16. Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors.
Carlsson T; Winkler C; Burger C; Muzyczka N; Mandel RJ; Cenci A; Björklund A; Kirik D
Brain; 2005 Mar; 128(Pt 3):559-69. PubMed ID: 15659429
[TBL] [Abstract][Full Text] [Related]
17. HIV-2 derived lentiviral vectors: gene transfer in Parkinson's and Fabry disease models in vitro.
D'Costa J; Harvey-White J; Qasba P; Limaye A; Kaneski CR; Davis-Warren A; Brady RO; Bankiewicz KS; Major EO; Arya SK
J Med Virol; 2003 Oct; 71(2):173-82. PubMed ID: 12938190
[TBL] [Abstract][Full Text] [Related]
18. [Gene therapy for Parkinson's disease: studies in animal models].
Muramatsu S
Rinsho Shinkeigaku; 2001 Dec; 41(12):1157-9. PubMed ID: 12235825
[TBL] [Abstract][Full Text] [Related]
19. [Ex vivo gene therapy in the treatment of Parkinson s disease].
García-Miniet R; Alberti-Amador E; Castellano-Ortega MR
Rev Neurol; 2003 Jun 1-15; 36(11):1073-7. PubMed ID: 12808505
[TBL] [Abstract][Full Text] [Related]
20. Viral-mediated temporally controlled dopamine production in a rat model of Parkinson disease.
Li XG; Okada T; Kodera M; Nara Y; Takino N; Muramatsu C; Ikeguchi K; Urano F; Ichinose H; Metzger D; Chambon P; Nakano I; Ozawa K; Muramatsu S
Mol Ther; 2006 Jan; 13(1):160-6. PubMed ID: 16182609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
